MacPherson Peter, Houben Rein M G J, Glynn Judith R, Corbett Elizabeth L, Kranzer Katharina
Department of Clinical Sciences, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, England .
Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, England .
Bull World Health Organ. 2014 Feb 1;92(2):126-38. doi: 10.2471/BLT.13.124800. Epub 2013 Nov 22.
To assess the magnitude of loss to follow-up in smear- or culture-positive tuberculosis patients before treatment initiation and outcomes among patients who were traced.
Ovid Medline and Global Health databases were searched for studies published between 1994 and January 2013 that described pre-treatment loss to follow-up in patients with smear- or culture-positive tuberculosis in routine national tuberculosis programmes (NTPs) in low- and lower-middle-income countries and in countries with a high burden of tuberculosis. Data on the proportion of patients who did not initiate treatment after their tuberculosis diagnosis were extracted from studies meeting inclusion criteria. Where available, data on causes and outcomes, including initiation of tuberculosis treatment at another facility, were investigated. Heterogeneity and publication bias were assessed and random-effects meta-analyses by subgroup (region) were performed.
Twenty-three eligible studies were identified, with a total of 34 706 smear- or culture-positive tuberculosis patients from 14 countries (8 in Africa, 5 in Asia and 1 in the western Pacific). Most studies were retrospective and linked laboratory and treatment registers to identify pre-treatment loss to follow-up. Pre-treatment loss to follow-up varied from 4 to 38% and was common in studies from Africa (random-effects weighted proportion, WP: 18%; 95% confidence interval, CI: 13-22) and Asia (WP: 13%; 95% CI: 10-15).
Pre-treatment loss to follow-up, common in most settings, can hinder tuberculosis control efforts. By not counting individuals who are lost to follow-up before treatment when reporting standard programme indicators, NTPs underestimate case detection rates and mortality and overestimate cure rates.
评估涂片或培养阳性的结核病患者在开始治疗前失访的程度以及追踪到的患者的治疗结果。
检索Ovid Medline和全球卫生数据库,查找1994年至2013年1月期间发表的研究,这些研究描述了低收入和中低收入国家以及结核病高负担国家的常规国家结核病规划(NTPs)中涂片或培养阳性的结核病患者治疗前的失访情况。从符合纳入标准的研究中提取结核病诊断后未开始治疗的患者比例数据。如有可用数据,调查原因和结果,包括在其他机构开始结核病治疗的情况。评估异质性和发表偏倚,并按亚组(地区)进行随机效应荟萃分析。
确定了23项符合条件的研究,共纳入来自14个国家(非洲8个、亚洲5个、西太平洋1个)的34706例涂片或培养阳性的结核病患者。大多数研究为回顾性研究,通过链接实验室和治疗登记册来确定治疗前的失访情况。治疗前失访率从4%到38%不等,在非洲的研究中较为常见(随机效应加权比例,WP:18%;95%置信区间,CI:13 - 22),在亚洲的研究中也较常见(WP:13%;95%CI:10 - 15)。
治疗前失访在大多数情况下较为常见,可能会阻碍结核病控制工作。在报告标准规划指标时,国家结核病规划未将治疗前失访的个体计算在内,从而低估了病例检出率和死亡率,高估了治愈率。